Sideromimic modification of lactivicin dramatically increases potency against extensively drug-resistant Stenotrophomonas maltophilia clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4170-4175

  Calvopiña, Karina ^a   Umland, Klaus Daniel ^b   Rydzik, Anna M ^b   Hinchliffe, Philip ^a   Brem, Jürgen ^b   Spencer, James ^a   Schofield, Christopher J ^b   Avison, Matthew B ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; LACTIVICIN; MEROPENEM; SIDEROPHORE; ANTIINFECTIVE AGENT; PEPTIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DRUG HYDROLYSIS; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STENOTROPHOMONAS MALTOPHILIA; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PEPTIDES; STENOTROPHOMONAS MALTOPHILIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84977110576     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00371-16     Document Type: Article

References (32)

1. Macheboeuf P, Fischer DS, Brown T, Jr, Zervosen A, Luxen A, Joris B, Dessen A, Schofield CJ. 2007. Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat Chem Biol 3:565-569. http://dx.doi.org/10.1038/nchembio.2007.21.
2. Nozaki Y, Katayama N, Ono H, Tsubotani S, Harada S, Okazaki H, Nakao Y. 1987. Binding of a non-β-lactam antibiotic to penicillin-binding proteins. Nature 325:179-180. http://dx.doi.org/10.1038/325179a0.
3. Nozaki Y, Katayama N, Harada S, Ono H, Okazaki H. 1989. Lactivicin, a naturally occurring non-β-lactam antibiotic having β-lactam-like action: biological activities and mode of action. J Antibiot (Tokyo) 42:84-93. http://dx.doi.org/10.7164/antibiotics.42.84.
4. Tamura N, Matsushita Y, Kawano Y, Yoshioka K. 1990. Synthesis and antibacterial activity of lactivicin derivatives. Chem Pharm Bull (Tokyo) 38:116-122. http://dx.doi.org/10.1248/cpb.38.116.
5. Brown T, Jr, Charlier P, Herman R, Schofield CJ, Sauvage E. 2010. Structural basis for the interaction of lactivicins with serine β-lactamases. J Med Chem 53:5890-5894. http://dx.doi.org/10.1021/jm100437u.
6. Starr J, Brown MF, Aschenbrenner L, Caspers N, Che Y, Gerstenberger BS, Huband M, Knafels JD, Lemmon MM, Li C, McCurdy SP, McElroy E, Rauckhorst MR, Tomaras AP, Young JA, Zaniewski RP, Shanmugasundaram V, Han S. 2014. Siderophore receptor-mediated uptake of lactivicin analogues in Gram-negative bacteria. J Med Chem 57:3845-3855. http://dx.doi.org/10.1021/jm500219c.
7. Ryan RP, Monchy S, Cardinale M, Taghavi S, Crossman L, Avison MB, Berg G, van der Lelie D, Dow JM. 2009. The versatility and adaptation of bacteria from the genus Stenotrophomonas. Nat Rev Microbiol 7:514-525. http://dx.doi.org/10.1038/nrmicro2163.
8. Brooke JS. 2012. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25:2-41. http://dx.doi.org/10.1128/CMR.00019-11.
9. Walsh TR, Hall L, Assinder SJ, Nichols WW, Cartwright SJ, MacGowan AP, Bennett PM. 1994. Sequence analysis of the L1 metallo-β-lactamase from Xanthomonas maltophilia. Biochim Biophys Acta 1218:199-201. http://dx.doi.org/10.1016/0167-4781(94)90011-6.
10. Walsh TR, MacGowan AP, Bennett PM. 1997. Sequence analysis and enzyme kinetics of the L2 serine β-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 41:1460-1464.
11. Gould VC, Okazaki A, Avison MB. 2006. β-Lactam resistance and β-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships. J Antimicrob Chemother 57:199-203. http://dx.doi.org/10.1093/jac/dki453.
12. Alonso A, Martínez JL. 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:3079-3086. http://dx.doi.org/10.1128/AAC.44.11.3079-3086.2000.
13. Gould VC, Avison MB. 2006. SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J Antimicrob Chemother 57:1070-1076. http://dx.doi.org/10.1093/jac/dkl106.
14. Chen CH, Huang CC, Chung TC, Hu RM, Huang YW, Yang TC. 2011. Contribution of resistance-nodulation-division efflux pump operon smeU1-V-W-U2-X to multidrug resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 55:5826-5833. http://dx.doi.org/10.1128/AAC.00317-11.
15. García-León G, Ruiz de Alegría Puig C, García de la Fuente C, Martínez-Martínez L, Martínez JL, Sánchez MB. 2015. High-level quinolone resistance is associated with the overexpression of smeVWX in Stenotrophomonas maltophilia clinical isolates. Clin Microbiol Infect 21:464-467. http://dx.doi.org/10.1016/j.cmi.2015.01.007.
16. Gould VC, Okazaki A, Avison MB. 2013. Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 57:655-657. http://dx.doi.org/10.1128/AAC.01020-12.
17. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. 2007. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 13:559-565. http://dx.doi.org/10.3201/eid1304.061378.
18. Avison MB, von Heldreich CJ, Higgins CS, Bennett PM, Walsh TR. 2000. A TEM-2 β-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J Antimicrob Chemother 46:879-884. http://dx.doi.org/10.1093/jac/46.6.879.
19. Avison MB, Underwood S, Okazaki A, Walsh TR, Bennett PM. 2004. Analysis of AmpC β-lactamase expression and sequence in biochemically atypical ceftazidime-resistant Enterobacteriaceae from paediatric patients. J Antimicrob Chemother 53:584-591. http://dx.doi.org/10.1093/jac/dkh151.
20. CLSI. 2015. M07-A10: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 10th ed. CLSI, Wayne, PA.
21. CLSI. 2015. M100-S25: performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI, Wayne, PA.
22. Talfan A, Mounsey O, Charman M, Townsend E, Avison MB. 2013. Involvement of mutation in ampD I, mrcA, and at least one additional gene in β-lactamase hyperproduction in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 57:5486-5491. http://dx.doi.org/10.1128/AAC.01446-13.
23. Ullah JH, Walsh TR, Taylor IA, Emery DC, Verma CS, Gamblin SJ, Spencer J. 1998. The crystal structure of the L1 metallo-β-lactamase from Stenotrophomonas maltophilia at 1.7 Å resolution. J Mol Biol 284:125-136. http://dx.doi.org/10.1006/jmbi.1998.2148.
24. Berrow NS, Alderton D, Sainsbury S, Nettleship J, Assenberg R, Rahman N, Stuart DI, Owens RJ. 2007. A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. Nucleic Acids Res 35:e45. http://dx.doi.org/10.1093/nar/gkm047.
25. Adams RW, Holroyd CM, Aguilar JA, Nilsson M, Morris GA. 2013. "Perfecting" WATERGATE: clean proton NMR spectra from aqueous solution. Chem Commun (Camb) 49:358-360. http://dx.doi.org/10.1039/C2CC37579F.
26. Hwang TL, Shaka AJ. 1998. Multiple-pulse mixing sequences that selectively enhance chemical exchange or cross-relaxation peaks in high-resolution NMR spectra. J Magn Reson 135:280-287. http://dx.doi.org/10.1006/jmre.1998.1598.
27. Okazaki A, Avison MB. 2008. Induction of L1 and L2 β-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator. Antimicrob Agents Chemother 52:1525-1528. http://dx.doi.org/10.1128/AAC.01485-07.
28. Lin CW, Lin HC, Huang YW, Chung TC, Yang TC. 2011. Inactivation of mrcA gene derepresses the basal-level expression of L1 and L2 β-lactamases in Stenotrophomonas maltophilia. J Antimicrob Chemother 66:2033-2037. http://dx.doi.org/10.1093/jac/dkr276.
29. Avison MB, Higgins CS, Ford PJ, von Heldreich CJ, Walsh TR, Bennett PM. 2002. Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia. J Antimicrob Chemother 49:387-389. http://dx.doi.org/10.1093/jac/49.2.387.
30. García CA, Passerini De Rossi B, Alcaraz E, Vay C, Franco M. 2012. Siderophores of Stenotrophomonas maltophilia: detection and determination of their chemical nature. Rev Argent Microbiol 44:150-154.
31. Page MG. 2013. Siderophore conjugates. Ann N Y Acad Sci 1277:115-126. http://dx.doi.org/10.1111/nyas.12024.
32. Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND, Mandrekar JN, Patel R. 2015. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 61:1071-1080. http://dx.doi.org/10.1093/cid/civ447.